Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials

BACKGROUND: Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD). However, different effects of pioglitazone on NAFLD have been demonstrated in diabetic and non-diabetic patients. Herein, a meta-analysis of randomized, placebo-controlled trials was carried out...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zeyu, Du, Huiqing, Zhao, Ying, Ren, Yadi, Ma, Cuihua, Chen, Hongyu, Li, Man, Tian, Jiageng, Xue, Caihong, Long, Guangfeng, Xu, Meidong, Jiang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091905/
https://www.ncbi.nlm.nih.gov/pubmed/37065735
http://dx.doi.org/10.3389/fendo.2023.1111430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091905/
https://www.ncbi.nlm.nih.gov/pubmed/37065735
http://dx.doi.org/10.3389/fendo.2023.1111430

Ejemplares similares